Edyta Paradowska

Edyta Paradowska

106 Lodowa St
Lodz, LD 93232, Poland

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 51 publications

TLR7 polymorphisms are associated with COVID-19 susceptibility and severity.

TLR7 polymorphisms are associated with COVID-19 susceptibility and severity.

Journal: Frontiers in immunology
Published: March 23, 2026

Glycoprotein N Associations With Congenital Cytomegalovirus Infection and Neurological Sequelae.

Glycoprotein N Associations With Congenital Cytomegalovirus Infection and Neurological Sequelae.

Journal: Journal of medical virology
Published: February 20, 2025

TLR8 and TLR9 gene polymorphisms and the risk of high-grade serous ovarian cancer.

TLR8 and TLR9 gene polymorphisms and the risk of high-grade serous ovarian cancer.

Journal: International journal of biological macromolecules
Published: July 19, 2024

Human papillomavirus infection of the fallopian tube as a potential risk factor for epithelial ovarian cancer.

Human papillomavirus infection of the fallopian tube as a potential risk factor for epithelial ovarian cancer.

Journal: Scientific reports
Published: April 19, 2024

Polymorphisms in the genes encoding RLR and TLR3 and CMV DNAemia in subjects coinfected with human immunodeficiency virus and cytomegalovirus.

Polymorphisms in the genes encoding RLR and TLR3 and CMV DNAemia in subjects coinfected with human immunodeficiency virus and cytomegalovirus.

Journal: Archives of virology
Published: March 04, 2024

Differential microRNA Expression Analysis in Patients with HPV-Infected Ovarian Neoplasms.

Differential microRNA Expression Analysis in Patients with HPV-Infected Ovarian Neoplasms.

Journal: International journal of molecular sciences
Published: December 01, 2023

Prediction of Chemoresistance-How Preclinical Data Could Help to Modify Therapeutic Strategy in High-Grade Serous Ovarian Cancer.

Prediction of Chemoresistance-How Preclinical Data Could Help to Modify Therapeutic Strategy in High-Grade Serous Ovarian Cancer.

Journal: Current oncology (Toronto, Ont.)
Published: November 13, 2023

High-Grade Serous Ovarian Cancer-A Risk Factor Puzzle and Screening Fugitive.

High-Grade Serous Ovarian Cancer-A Risk Factor Puzzle and Screening Fugitive.

Journal: Biomedicines
Published: November 12, 2023

Personalization of Therapy in High-Grade Serous Tubo-Ovarian Cancer-The Possibility or the Necessity?

Personalization of Therapy in High-Grade Serous Tubo-Ovarian Cancer-The Possibility or the Necessity?

Journal: Journal of personalized medicine
Published: November 12, 2023

"DEPHENCE" system-a novel regimen of therapy that is urgently needed in the high-grade serous ovarian cancer-a focus on anti-cancer stem cell and anti-tumor microenvironment targeted therapies.

"DEPHENCE" system-a novel regimen of therapy that is urgently needed in the high-grade serous ovarian cancer-a focus on anti-cancer stem cell and anti-tumor microenvironment targeted therapies.

Journal: Frontiers in oncology
Published: April 06, 2023

Endometriosis Stem Cells as a Possible Main Target for Carcinogenesis of Endometriosis-Associated Ovarian Cancer (EAOC).

Endometriosis Stem Cells as a Possible Main Target for Carcinogenesis of Endometriosis-Associated Ovarian Cancer (EAOC).

Journal: Cancers
Published: November 27, 2022

The Toll-like Receptor 4 Polymorphism Asp299Gly Is Associated with an Increased Risk of Ovarian Cancer.

The Toll-like Receptor 4 Polymorphism Asp299Gly Is Associated with an Increased Risk of Ovarian Cancer.

Journal: Cells
Published: August 27, 2022
Showing 1-12 of 51

Last Updated: 09/26/2026